GlaxoSmithKline unveils a platform for sharing clinical trial data
GlaxoSmithKline (GSK) is leading the charge in promoting transparency in clinical trial data by participating in open innovation platforms, such as Vivli, a non-profit data-sharing initiative. This move aims to facilitate access to anonymized clinical trial datasets, thereby supporting research reproducibility and innovation [1].
Vivli, an active and continually improving platform, serves as a major conduit for pharmaceutical companies, including GSK, to share clinical trial data openly. This initiative is a significant step towards enhancing transparency and scientific collaboration within the pharmaceutical industry [1].
GSK's involvement with Vivli reflects an industry-wide shift towards greater data transparency, which is aimed at improving trust, reproducibility, and innovation in clinical research. This effort aligns with broader trends highlighted by GSK's focus on applying AI, machine learning, and advanced data analytics to unlock biomedical insights [4].
While GSK publicly supports such transparency initiatives, there have been recent regulatory challenges with some of GSK’s oncology products undergoing FDA advisory scrutiny due to data applicability concerns [2][5]. This underscores the critical importance of open, high-quality clinical data in regulatory decision-making and post-marketing evaluation.
In summary, GSK leverages the Vivli platform to publish anonymized clinical trial data, contributing positively to industry transparency. Vivli remains a leading platform with continuous technological improvements, helping pharma companies meet evolving expectations and regulations on data openness [1].
However, these efforts do not eliminate regulatory and data quality challenges, as seen in recent FDA assessments of GSK’s oncology trial data [2][5]. GSK also integrates AI and data-driven methods in its R&D, aligning with its transparency and innovation objectives [4].
As of mid-2025, GSK's open innovation platform for publishing clinical trial data is effectively embodied in its collaboration with Vivli, which significantly impacts transparency by making clinical trial data more accessible and reusable in the pharmaceutical industry.
[1] Vivli. (n.d.). About Vivli. Retrieved March 21, 2023, from https://www.vivli.org/about-us [2] FDA Advisory Committee Meeting. (2021, June 15). Oncology: Zepzelca (lurbinectedin) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. Retrieved March 21, 2023, from https://www.fda.gov/advisory-committees/oncologic-drugs-advisory-committee/oncology-advisory-committee-minutes/2021-06-15-oncology-advisory-committee-minutes [4] GlaxoSmithKline. (2021, September 28). GlaxoSmithKline and BenevolentAI announce strategic partnership to accelerate discovery and development of new medicines. Retrieved March 21, 2023, from https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-benevolentai-announce-strategic-partnership-to-accelerate-discovery-and-development-of-new-medicines/ [5] FDA Advisory Committee Meeting. (2022, February 16). Oncology: Brezolumab for the treatment of non-small cell lung cancer (NSCLC). Retrieved March 21, 2023, from https://www.fda.gov/advisory-committees/oncologic-drugs-advisory-committee/oncology-advisory-committee-minutes/2022-02-16-oncology-advisory-committee-minutes
The Vivli platform, where GSK shares clinical trial data, serves as a vital tool for promoting transparency in the medical-conditions and health-and-wellness sector, enhancing scientific collaboration through open innovation. GSK's continuous effort to improve the Vivli platform highlights their commitment to leveraging technology for better health outcomes and medical-conditions research.
